Skip to main content

Advertisement

Table 3 Meta-analysis of suicide-related events in acute paediatric active comparator-controlled atomoxetine studies–ADHD (FDA-defined approach)

From: Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials

  Atomoxetine Methylphenidate MHRRa(95% CI) p-value MHIDb(%) (95% CI) p-value
Outcome No. of events N % No. of events N %   
Code 1,2,3,4: suicidal behaviour or ideation 1 559 0.18 1 465 0.22 0.52 (95% CI; 0.06, 4.54) P = 0.556 -0.12 (-0.62, 0.38) P = 0.649
Code 4: Suicidal ideation 1 559 0.18 1 465 0.22 0.52 (95% CI; 0.06, 4.54) P = 0.556 -0.12 (-0.62, 0.38) P = 0.649
Code 1,2,3,4,5,6,9: possible suicidal behaviour or ideation 3 559 0.54 2 465 0.43 0.62 (95% CI; 0.14, 2.73) P = 0.528 -0.14 (-0.88, 0.60) P = 0.713
  1. aMHRR Mantel-Haenszel risk ratio stratified by study. It is the estimate of the percentage among atomoxetine-treated patients over the percentage among methylphenidate-treated patients.
  2. bMHID Mantel-Haenszel incidence difference stratified by study. It is the estimate of the percentage among atomoxetine-treated patients minus the percentage among methylphenidate-treated patients in percentage units.